Emerging Substances: Xylazine, Kratom, CBD, and THC – What Are Patients Asking? - SCS41

Saturday, May 18, 2024

1:15 PM – 2:15 PM PDT

Location: 306-314

CME Credits 1

Niraj R. Chavan, MD, MPH, MS (he/him/his)

Associate Professor, Program Director - Maternal Fetal Medicine Fellowship
Dept. of Obstetrics, Gynecology & Women's Health, Saint Louis University
Saint Louis University/SSM Health
St. Louis, MO, United States
Maria Manriquez, MD, FACOG

Professor and Director, Addiction Medicine Perinatal Service
University of Arizona College of Medicine Phoenix
University of Arizona College of Medicine Phoenix, Banner University Medical Center Phoenix
Phoenix, AZ, United States
Cresta W. Jones, MD, FACOG (she/her/hers)

Associate Professor
University of Minnesota Medical School
University of Minnesota
Minneapolis, MN, United States

Session Description
This session will address the perinatal impact of emerging topics related to substance use/misuse. It will provide an introduction to newer paradigms of care such as perinatal harm reduction and adaptations to clinical practice in the face of the evolving medicolegal landscape for specific substances (eg, medicinal and recreational cannabis legalization). Importantly, this session will provide much-needed answers to questions such as, what should every practicing obstetrician–gynecologist know and be ready for in the context of emerging substances of use/misuse, and how should our practices change in the context of the shifting cannabis legalization environment?

Disclosure(s):

Niraj R. Chavan, MD: No financial relationships to disclose